Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4522904

CN1CCN(c2cnc3ccccc3c2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 4/20 0.76
AKR1C3 P42330 1/20 0.56
DRD3 P35462 2/20 0.53
DRD2 P14416 1/20 0.53
MET P08581 3/20 0.52
DHFR P00374 1/20 0.49
CHRNB2 P17787 1/20 0.49
CHRNA4 P43681 1/20 0.49
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
C1S P09871 1/20 0.47
CCKAR P32238 4/20 0.46
ABL1 P00519 1/20 0.46
KIT P10721 1/20 0.46
BCR P11274 1/20 0.46
DDR1 Q08345 1/20 0.46
DDR2 Q16832 1/20 0.46
HRH4 Q9H3N8 2/20 0.46
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352883 0.87 HTR3A (1.00) HTR3AAKR1C3DRD3DRD2MET
SCHEMBL6348984 0.82 HTR3A (0.89) HTR3AAKR1C3DRD3DRD2MET
SCHEMBL5317286 0.79 AKR1C3 (0.70) HTR3AAKR1C3DRD3DRD2DHFR
Oxalic Acid SCHEMBL8147179 0.77 CHRNB2 (0.63) HTR3AAKR1C3DRD3DRD2DHFR
SCHEMBL4054998 0.75 AKR1C3 (0.61) HTR3AAKR1C3METDHFRCCKAR
SCHEMBL31254486 0.75 AKR1C3 (0.61) HTR3AAKR1C3METDHFRCCKAR
SCHEMBL5800979 0.74 HTR3A (0.58) HTR3AAKR1C3DRD3DRD2DHFR
Trifluoroacetic Acid SCHEMBL29876164 0.74 ADRA2A (0.55)
Trifluoroacetic Acid SCHEMBL28891676 0.74 ADRA2A (0.55)
SCHEMBL20274184 0.73 AKR1C3 (0.66) HTR3AAKR1C3DRD3DRD2DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
CN-101137645-A Arylpiperazine derivatives for the treatment of neuropsychiatric disorders UNIV SIENA (IT) 2008-03-05 CN disclosed
EP-1836192-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS Universita' Degli Studi di Siena (IT) 2007-09-26 EP disclosed
WO-2006072608-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS UNIVERSITÁ DEGLI STUDI DI SIENA (IT) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility HTR2C, HTR2A, DRD2 HTR3A 5/4885AKR1C3 2624/4885DRD3 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.